Pluri Inc. — Investor Presentation 2015

May 4, 2015

Pluristem Therapeutics Inc.

Pluristem to Present at Five Industry and Finance Conferences in May

HAIFA, ISRAEL, May 4, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced that its executives will present at the following regenerative medicine and finance conferences during the month of May:

International Society for Pharmaceutical Engineering Europe Annual Conference

Date: 9:10 a.m. on Wednesday, May 6 2015

Location: Frankfurt, Germany

Presentation Title: Flexible Manufacturing of Cell Therapy Product, Challenges and Possible Solutions

Presented by: Nadav Eshkol, Team Leader, Process Development

Israel Advanced Technology Industries Biomed Israel 2015

Date: 5:10 p.m. on Wednesday, May 13 2015

Location: Tel Aviv, Israel

Presentation Title: Regenerative Medicine - When Placental Cells Meet Technology

Presented by: Yaky Yanay, President & COO

Oppenheimer’s 16th Annual Israeli Conference

Date: Sunday, May 10 2015

Location: Tel Aviv, Israel

Presentation by: Zami Aberman, Chairman & CEO

Hong Kong-Israel “Game Changing” Investments

Date: Wednesday, May 20 2015

Locations: Hong Kong

Presentation by: Yaky Yanay, President & COO

2015 Capvision “Internet+” Healthcare Investment Summit

Date: Thursday, May 21 2015

Location: Beijing, China

Presentation by: Yaky Yanay, President & COO

About Pluristem Therapeutics

---

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

Contact:

Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com